{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:16:57Z","timestamp":1793395017442,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160697"],"award-info":[{"award-number":["82160697"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22467015"],"award-info":[{"award-number":["22467015"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82560718"],"award-info":[{"award-number":["82560718"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003996","name":"Kunming Medical University","doi-asserted-by":"publisher","award":["202201AY070001-006"],"award-info":[{"award-number":["202201AY070001-006"]}],"id":[{"id":"10.13039\/501100003996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003996","name":"Kunming Medical University","doi-asserted-by":"publisher","award":["2024XKTDTS12"],"award-info":[{"award-number":["2024XKTDTS12"]}],"id":[{"id":"10.13039\/501100003996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007846","name":"Yunnan Provincial Department of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007846","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bcp.2026.117903","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T15:44:17Z","timestamp":1773589457000},"page":"117903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Ticagrelor reverses multidrug resistance in breast cancer by inhibiting PI3K\/AKT\/mTOR pathway and suppressing ABCB1 expression and function"],"prefix":"10.1016","volume":"249","author":[{"given":"Hongyan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shicheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5852-3953","authenticated-orcid":false,"given":"Hongyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.117903_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bcp.2026.117903_b0010","first-page":"721","article-title":"Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives","volume":"15","author":"Wang","year":"2023","journal-title":"Breast Cancer"},{"key":"10.1016\/j.bcp.2026.117903_b0015","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2026.117903_b0020","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.bcp.2026.117903_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1139\/bcb-2024-0264","article-title":"Doxorubicin, a DNA intercalator, inhibits transcription elongation","volume":"103","author":"Tempel","year":"2025","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/j.bcp.2026.117903_b0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2026.117903_b0035","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2026.117903_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116850","article-title":"Strategic advancements in targeting the PI3K\/AKT\/mTOR pathway for Breast cancer therapy","volume":"236","author":"Garg","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117903_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177432","article-title":"Targeting PI3K in cancer treatment: a comprehensive review with insights from clinical outcomes","volume":"996","author":"Hossain","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117903_b0050","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41416-025-03035-z","article-title":"Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kalpha potently inhibits the PI3K\/AKT\/mTOR pathway in endometrial and breast cancer models","volume":"133","author":"Tyrakis","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2026.117903_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2024.08.001","article-title":"Nutrient sensing of mTORC1 signaling in cancer and aging","volume":"106\u2013107","author":"Jiang","year":"2024","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2026.117903_b0060","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/onc.2016.363","article-title":"mTORC1 and mTORC2 in cancer and the tumor microenvironment","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.117903_b0065","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/978-3-030-20301-6_15","article-title":"Role of mTORC1 and mTORC2 in breast cancer: therapeutic targeting of mTOR and its partners to overcome metastasis and drug resistance","volume":"1152","author":"Butt","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bcp.2026.117903_b0070","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12943-022-01524-w","article-title":"CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1\/P-gp mediated multi-drug resistance (MDR) in cancer cells","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2026.117903_b0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-019-1112-1","article-title":"The PI3K subunits, P110alpha and P110beta are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2026.117903_b0080","article-title":"A dual PI3 kinase\/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines","volume":"1864","author":"Durrant","year":"2020","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2026.117903_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177955","article-title":"Pharmacology and clinical outcomes of ticagrelor in acute coronary syndrome and post-myocardial infarction patients: a meta-analysis","volume":"1003","author":"Dave","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117903_b0090","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ijc.28947","article-title":"The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer","volume":"136","author":"Gebremeskel","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2026.117903_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116408","article-title":"Antiplatelet drug ticagrelor suppresses triple negative breast cancer metastasis by targeting PI3K","volume":"226","author":"Wang","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117903_b0100","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2174\/1568009616666151113120705","article-title":"Understanding cancer drug resistance by developing and studying resistant cell line models","volume":"16","author":"Xavier","year":"2016","journal-title":"Curr. Cancer Drug Targets"},{"issue":"Pt 11","key":"10.1016\/j.bcp.2026.117903_b0105","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1242\/jcs.113.11.2011","article-title":"The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)","volume":"113","author":"Litman","year":"2000","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bcp.2026.117903_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113774","article-title":"EMT mechanism in breast cancer metastasis and drug resistance: revisiting molecular interactions and biological functions","volume":"155","author":"Hashemi","year":"2022","journal-title":"Biomed. Pharmacother"},{"key":"10.1016\/j.bcp.2026.117903_b0115","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1038\/onc.2010.215","article-title":"EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer","volume":"29","author":"Singh","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.117903_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.628690","article-title":"Activation of PI3K\/AKT\/mTOR pathway causes drug resistance in breast cancer","volume":"12","author":"Dong","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117903_b0125","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.2174\/0109298673327425240815065221","article-title":"A perspective of PI3K\/AKT\/mTOR pathway inhibitors to overcome drug-resistance in breast cancer therapy","volume":"32","author":"Mandal","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2026.117903_b0130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2141.1992.tb04608.x","article-title":"Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123","volume":"82","author":"Ludescher","year":"1992","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcp.2026.117903_b0135","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1021\/acs.biomac.7b00291","article-title":"Reversion of P-gp-mediated drug resistance in ovarian carcinoma cells with PHPMA-zosuquidar conjugates","volume":"18","author":"Battistella","year":"2017","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.bcp.2026.117903_b0140","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70803","article-title":"Targeting triple-negative breast cancer: resistance mechanisms and therapeutic advancements","volume":"14","author":"Raman","year":"2025","journal-title":"Cancer Med."},{"key":"10.1016\/j.bcp.2026.117903_b0145","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/1061186X.2022.2091578","article-title":"ABC transporters in breast cancer: their roles in multidrug resistance and beyond","volume":"30","author":"Modi","year":"2022","journal-title":"J. Drug Target."},{"key":"10.1016\/j.bcp.2026.117903_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117486","article-title":"The mechanisms of multidrug resistance of breast cancer and research progress on related reversal agents","volume":"95","author":"Yu","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2026.117903_b0155","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","article-title":"Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms","volume":"44","author":"Jain","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.117903_b0160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12967-023-04841-w","article-title":"Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway","volume":"22","author":"Tufail","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2026.117903_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107077","article-title":"A comprehensive review of small molecules targeting PI3K pathway: Exploring the structural development for the treatment of breast cancer","volume":"143","author":"Dubey","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bcp.2026.117903_b0170","doi-asserted-by":"crossref","first-page":"560","DOI":"10.20517\/cdr.2022.41","article-title":"Aberrant calcium signalling downstream of mutations in TP53 and the PI3K\/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer","volume":"5","author":"Eustace","year":"2022","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.bcp.2026.117903_b0175","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.3390\/cancers17132232","article-title":"The PI3K\/Akt\/mTOR signaling pathway in triple-negative breast cancer: a resistance pathway and a prime target for targeted therapies","volume":"17","author":"Hassan","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2026.117903_b0180","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clbc.2017.10.014","article-title":"A phase I trial of the PI3K inhibitor buparlisib combined with capecitabine in patients with metastatic breast cancer","volume":"18","author":"McRee","year":"2018","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.bcp.2026.117903_b0185","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13058-018-1015-x","article-title":"A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer","volume":"20","author":"Schoffski","year":"2018","journal-title":"Breast Cancer Res.: BCR"},{"key":"10.1016\/j.bcp.2026.117903_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114822","article-title":"Discovery of a novel highly potent and low-toxic jatrophane derivative enhancing the P-glycoprotein-mediated doxorubicin sensitivity of MCF-7\/ADR cells","volume":"244","author":"Maimaitijiang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.117903_b0195","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/jcb.24533","article-title":"Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7\/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation","volume":"114","author":"Shi","year":"2013","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bcp.2026.117903_b0200","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1538-7836.2009.03527.x","article-title":"Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation","volume":"7","author":"Jj","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcp.2026.117903_b0205","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1074248413511693","article-title":"Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1","volume":"19","author":"Armstrong","year":"2014","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2026.117903_b0210","article-title":"Novel cancer-fighting role of ticagrelor inhibits GTSE1-induced EMT by regulating PI3K\/Akt\/NF-kappaB signaling pathway in malignant glioma","volume":"10","author":"Lu","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bcp.2026.117903_b0215","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/14656566.2013.757303","article-title":"Ticagrelor: the first novel reversible P2Y(12) inhibitor","volume":"14","author":"Htun","year":"2013","journal-title":"Expert Opin. Pharmacother."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:14:27Z","timestamp":1778710467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226002364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":43,"alternative-id":["S0006295226002364"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117903","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ticagrelor reverses multidrug resistance in breast cancer by inhibiting PI3K\/AKT\/mTOR pathway and suppressing ABCB1 expression and function","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117903"}}